Skip to main content

Table 1 Drug-pathway association in the DTPN of Luminal A subtype

From: In silico identification of drug target pathways in breast cancer subtypes using pathway cross-talk inhibition

Drug

Pathway

nNE and PCI (vs NE = 0.3218)

Capecitabine

Eicosanoid

0.3194 (PCI 0.75%)

Fulvestrant

Bladder cancer signaling (1); estrogen receptor (2); regulation of cellular mechanics by calpain protease (3)

(1) 0.3179 (PCI 1.18%)

(2) 0.3137 (PCI 2.50%)

(3) 0.3198 (PCI 0.59%)

(1–2) 0.3094 (PCI 3.84%)

(1–3) 0.3159 (PCI 1.81%)

(2–3) 0.3115 (PCI 3.18%)

(1–2–3) 0.3071 (PCI 4.56%)

Gemcitabine

Regulation of cellular mechanics by calpain protease

0.3198 (PCI 0.59%)

Methotrexate

FXR/RXR activation

0.3193 (PCI 0.75%)

Raloxifene

Estrogen receptor (1); RAR activation (2)

(1) 0.3137 (PCI 2.50%)

(2) 0.3170 (PCI 1.47%)

(1–2) 0.3098 (PCI 3.70%)

Tamoxifen

Estrogen receptor (1); factors promoting cardiogenesis in vertebrates (2); human embryonic stem cell pluripotency (3); RAR activation (4)

(1) 0.3137 (PCI 2.50%)

(2) 0.3180 (PCI 1.17%)

(3) 0.3157 (PCI 1.86%)

(4) 0.3170 (PCI 1.47%)

(1–2) 0.3092 (PCI 3.88%)

(1–3) 0.3071 (PCI 4.56%)

(1–4) 0.3098 (PCI 3.70%)

(2–3) 0.3098 (PCI 3.70%)

(2–4) 0.3129 (PCI 2.74%)

(3–4) 0.3103 (PCI 3.56%)

(1–2–3) 0.3003 (PCI 6.68%)

(2–3–4) 0.3025 (PCI 5.98%)

(3–4–1) 0.3051 (PCI 5.18%)

(1–2–3–4) 0.2941 (PCI 8.59%)

Toremifene

FXR/RXR activation (1); pregnenolone biosynthesis (2)

(1) 0.3193 (PCI 0.75%)

(2) 0.3192 (PCI 0.79%)

(1–2) 0.3165 (PCI 1.61%)

Vinblastine

Axonal guidance signaling (1); FXR/RXR activation (2)

(1) 0.3216 (PCI 0.05%)

(2) 0.3193 (PCI 0.75%)

(1–2) 0.3190 (PCI 0.86%)